Literature DB >> 15254195

APOBEC3G targets specific virus species.

Masayuki Kobayashi1, Akifumi Takaori-Kondo, Keisuke Shindo, Aierken Abudu, Keiko Fukunaga, Takashi Uchiyama.   

Abstract

Human APOBEC3G (huAPOBEC3G), also known as CEM15, is a broad antiretroviral host factor that deaminates dC to dU in the minus strand DNA of human immunodeficiency virus type 1 (HIV-1), other lentiviruses, and murine leukemia virus (MLV), thereby creating G-to-A hypermutation in the plus strand DNA to inhibit the infectivity of these viruses. In this study, we examined the antiretroviral function of a murine homologue of APOBEC3G (muAPOBEC3G) on several retrovirus systems with different producer cells. MuAPOBEC3G did not suppress the infectivity of murine retroviral vectors produced from human or murine cells, whereas it showed antiviral activity on both wild-type and Deltavif virions of HIV-1 in human cells. In contrast, huAPOBEC3G showed broad antiviral activity on HIV-1 and murine retroviral vectors produced from human cells as well as murine cells. These data suggested that muAPOBEC3G does not possess antiretroviral activity on murine retroviruses and has a different target specificity from that of huAPOBEC3G and that huAPOBEC3G works as a broad antiviral factor not only in human cells but also in murine cells. A functional interaction study between human and murine APOBEC3G supported the former hypothesis. Furthermore, studies on the expression of APOBEC3G in producer cells and its incorporation into virions revealed that muAPOBEC3G is incorporated into HIV-1 virions but not into MLV virions. Thus, muAPOBEC3G cannot suppress the infectivity of murine retrovirus because it is not incorporated into virions. We suggest that murine retroviruses can replicate in murine target cells expressing muAPOBEC3G because they are not targets for this enzyme.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254195      PMCID: PMC446120          DOI: 10.1128/JVI.78.15.8238-8244.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses.

Authors:  Reuben S Harris; Ann M Sheehy; Heather M Craig; Michael H Malim; Michael S Neuberger
Journal:  Nat Immunol       Date:  2003-07       Impact factor: 25.606

2.  Good to CU.

Authors:  Yapeng Gu; Wesley I Sundquist
Journal:  Nature       Date:  2003-07-03       Impact factor: 49.962

Review 3.  Death by deamination: a novel host restriction system for HIV-1.

Authors:  Stephen P Goff
Journal:  Cell       Date:  2003-08-08       Impact factor: 41.582

4.  The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.

Authors:  Keisuke Shindo; Akifumi Takaori-Kondo; Masayuki Kobayashi; Aierken Abudu; Keiko Fukunaga; Takashi Uchiyama
Journal:  J Biol Chem       Date:  2003-09-11       Impact factor: 5.157

5.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

6.  Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.

Authors:  Roberto Mariani; Darlene Chen; Bärbel Schröfelbauer; Francisco Navarro; Renate König; Brooke Bollman; Carsten Münk; Henrietta Nymark-McMahon; Nathaniel R Landau
Journal:  Cell       Date:  2003-07-11       Impact factor: 41.582

7.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.

Authors:  Hui Zhang; Bin Yang; Roger J Pomerantz; Chune Zhang; Shyamala C Arunachalam; Ling Gao
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

8.  HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.

Authors:  Mariana Marin; Kristine M Rose; Susan L Kozak; David Kabat
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

9.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Authors:  Kim Stopak; Carlos de Noronha; Wes Yonemoto; Warner C Greene
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

10.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.

Authors:  Ann M Sheehy; Nathan C Gaddis; Michael H Malim
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

View more
  55 in total

1.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

2.  Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.

Authors:  Tobias Paprotka; Narasimhan J Venkatachari; Chawaree Chaipan; Ryan Burdick; Krista A Delviks-Frankenberry; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

Review 3.  Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.

Authors:  Bryan R Cullen
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 4.  APOBEC family proteins: novel antiviral innate immunity.

Authors:  Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

5.  Restriction of foamy viruses by APOBEC cytidine deaminases.

Authors:  Frédéric Delebecque; Rodolphe Suspène; Sara Calattini; Nicoletta Casartelli; Ali Saïb; Alain Froment; Simon Wain-Hobson; Antoine Gessain; Jean-Pierre Vartanian; Olivier Schwartz
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet.

Authors:  Mario Perkovic; Stanislaw Schmidt; Daniela Marino; Rebecca A Russell; Benjamin Stauch; Henning Hofmann; Ferdinand Kopietz; Björn-Philipp Kloke; Jörg Zielonka; Heike Ströver; Johannes Hermle; Dirk Lindemann; Vinay K Pathak; Gisbert Schneider; Martin Löchelt; Klaus Cichutek; Carsten Münk
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

7.  Core Binding Factor β Protects HIV, Type 1 Accessory Protein Viral Infectivity Factor from MDM2-mediated Degradation.

Authors:  Yusuke Matsui; Keisuke Shindo; Kayoko Nagata; Noriyoshi Yoshinaga; Kotaro Shirakawa; Masayuki Kobayashi; Akifumi Takaori-Kondo
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

8.  Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation.

Authors:  Hal P Bogerd; Bryan R Cullen
Journal:  RNA       Date:  2008-05-02       Impact factor: 4.942

9.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

10.  Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1.

Authors:  Lindi Tan; Phuong Thi Nguyen Sarkis; Tao Wang; Chunjuan Tian; Xiao-Fang Yu
Journal:  FASEB J       Date:  2008-09-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.